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Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity
against Influenza A and B Viruses
Giulia Muratore,a Beatrice Mercorelli,a Laura Goracci,b Gabriele Cruciani,b Paul Digard,c Giorgio Palù,a and Arianna Loregiana
Department of Molecular Medicine, University of Padua, Padua, Italya; Department of Chemistry, University of Perugia, Perugia, Italyb; and Roslin Institute, University of
Edinburgh, Easter Bush, Midlothian, United Kingdomc
AL18, an inhibitor of human cytomegalovirus DNA polymerase, was serendipitously found to also block the interaction
between the PB1 and PA polymerase subunits of influenza A virus. Furthermore, AL18 effectively inhibited influenza A
virus polymerase activity and the overall replication of influenza A and B viruses. A molecular model to explain the bind-
ing of AL18 to both cytomegalovirus and influenza targets is proposed. Thus, AL18 represents an interesting lead for the
development of new antivirals.
Influenza A virus is a major human pathogen responsible forrespiratory diseases characterized by high morbidity and signif-
icant mortality. Influenza A causes seasonal epidemics affecting
millions of people worldwide but can also provoke pandemic out-
breaks with higher attack rates and potentially more-severe dis-
ease (18).
Currently, two classes of anti-influenza A drugs are available:
adamantanes, which block the M2 ion channel and inhibit virus
entry, and neuraminidase inhibitors, which prevent the release of
virions from the host cell (5).However, they all suffer from limited
efficacy, adverse side effects, and emergence of drug resistance.
Vaccines also exist, but they must be reformulated annually and
they give limited protection. Thus, there is still a considerable need
for new anti-influenza drugs.
The influenza A RNA polymerase, a heterotrimer of the PA,
PB1, and PB2 subunits, provides an underexploited drug target.
The three subunits bind each other and are all essential for viral
RNA synthesis (18). Recent crystal structures revealed that the
PA-PB1 binding interface consists of an N-terminal helix from
PB1 that binds into a groove in the C terminus of PA (7, 17). Since
the association of these subunits is essential for viral replication
(19), and since the amino acids of both PB1 andPA that are crucial
for subunit interaction are highly conserved among influenza A
strains (6, 10), this interaction represents an attractive target for
antiviral drugs. To this end, we recently developed a PA-PB1 in-
teraction assay and used it to identify compounds able to inhibit
the interaction (16).
In these influenza A PB1-PA binding assays, microtiter wells
coated with 6His-PA239-716, a 6His-tagged form of the PA C-ter-
minal domain, are incubated with glutathione S-transferase
(GST)-PB11-25, a GST fusion with the N-terminal 25 residues of
PB1 (which are sufficient to bind the PA C-terminal domain [6,
7]), in the absence or the presence of test compounds. Active
inhibitors, such as a PB1-derived peptide fused to sequences from
HIV Tat (PB11-15-Tat [6]) or the small-molecule “compound 1”
inhibitor we recently identified (16), effectively blocked the PA-
PB1 interaction as expected (Fig. 1). During the course of these
studies, we also tested small molecules able to disrupt the interac-
tion between the UL54 and UL44 subunits of human cytomega-
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FIG 1 (A) Chemical structures of AL18, AL5, and compound 1. (B) Effects of AL18 on PA-PB1 interactions. Increasing concentrations of the indicated
compounds were added together with 200 ng of GST-PB11-25 to wells coated with 400 ng of 6His-PA239-716. Binding of GST-PB11-25 to 6His-PA239-716 was
detected with a horseradish peroxidase (HRP)-conjugated anti-GST antibody, followed by measurement of the absorbance at 450 nm. Data shown are the
means  standard deviations (SDs) of three independent experiments.
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lovirus (HCMV) DNA polymerase (13), expecting them to pro-
vide negative controls. Unexpectedly, the most active of the
HCMV inhibitors, AL18, also inhibited the PA-PB1 interaction
with a 50% inhibitory concentration (IC50; calculated by linear
regression using the computer program GraphPad Prism version
4.0) of 20.3  2.6 M (Fig. 1). In contrast, another of the previ-
ously characterized UL54-UL44 inhibitors, AL5 (13), did not af-
fect PA-PB1 binding (Fig. 1).
To investigate whether the in vitro inhibitory activity of AL18
on the minimal PA-PB1 binding domains was matched by a cor-
responding effect on the influenza A transcription machinery in
cells, the compound was tested in influenza Aminireplicon assays
(15, 16). Ribavirin (RBV; from Roche), a known inhibitor of viral
RNA polymerases (20), and the anti-PA-PB1 compound 1 served
as positive controls. Human embryonic kidney (HEK) 293T cells
were cotransfected with plasmids encoding the three polymerase
subunits and the viral nucleoprotein (NP) along with a plasmid
carrying the firefly luciferase reporter gene flanked by the noncod-
ing sequences of influenza A (A/WSN/33 strain) segment 8 and a
plasmid coding forRenilla luciferase (pRL-SV40; Promega)which
served to normalize variations in transfection efficiency, and the
cells were treated with test or control compounds. The firefly re-
porter gene expression indicates that a negative-sense RNA is syn-
FIG 2 Ability of AL18 to inhibit influenza A polymerase activity in minirep-
licon assays. HEK 293T cells were cotransfected with plasmids encoding PB1,
PB2, PA, and NP along with a plasmid carrying the firefly luciferase reporter
gene flanked by the noncoding sequences of influenza A segment 8 and treated
with the indicated compounds. The transfection mixtures also contained a
plasmid constitutively expressing Renilla luciferase which served to normalize
variations in transfection efficiency. Luciferase activity was quantified at 24 h
posttransfection. The data are the means SDs of three independent experi-
ments plotted relative to the activity seen in the presence of the compound
vehicle (dimethyl sulfoxide [DMSO]). Omission of PB2 served as a negative
control.
FIG 3 Activity of AL18 against influenza A replication. (A) Effects of the indicated compounds on plaque formation by A/PR/8/34 virus in MDCK cells.
Representative pictures of mock-infected (PR8), A/PR/8/34-infected untreated (PR8/AL18), and A/PR/8/34-infected, AL18-treated (PR8/AL18) cells
are shown on the right. (B) Effects of AL18 (left) and of RBV as a control (right) on the yield of A/PR/8/34 virus following low-MOI infections of MDCK
cells, determined at 12, 24, and 48 h p.i. (C) Inhibition of A/PR/8/34 virus replication by AL18 and by compound 1 added at different times before or during the
viral life cycle. Data shown in panels A, B, and C are the means SDs of two or three independent experiments in duplicate.
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thesized and is reconstituted intracellularly into functional RNPs
in which all four viral proteins are coexpressed and interact with
each other. A strong inhibition of firefly luciferase activity, mea-
sured at 24 h posttransfection (Fig. 2), was observed upon treat-
ment with AL18 (50% effective concentration [EC50], calculated
by linear regression using GraphPad Prism 4.0, of 16.5 3.5M)
and, as expected, with RBV and compound 1 (EC50s of 26.5 4.8
M and 18.4 4.5 M, respectively), whereas AL5 had no effect
(EC50 100 M).
Next, the effect of AL18 on the replication of influenza A (A/
PR/8/34 strain, from the Department of Pathology, University of
Cambridge, United Kingdom) in Madin-Darby canine kidney
(MDCK) cells was evaluated by plaque reduction assays (PRAs) as
described previously (16). AL18 inhibited influenza A plaque for-
mation in a dose-dependent manner (Fig. 3A), with EC50s similar
to those of compound 1 (EC50swere 14.5 2.1Mand 19.4 3.2
M, respectively) (Fig. 3A and Table 1), while AL5 did not show
significant activity (EC50 100 M) (Fig. 3A). In addition, AL18
showed antiviral activity against several influenza A strains, in-
cluding pandemic swine-originated influenza virus strains (from
C. Salata, University of Padua, Italy) and an oseltamivir-resistant
clinical isolate (A/Parma/24/09; from I. Donatelli, Istituto Supe-
riore di Sanità, Rome, Italy), with EC50s ranging from 13.5 to 27.8
M. In parallel, we tested the cytotoxicity of the compound both
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT; Sigma) assays (16) and by using a bioluminescence-
based ATP determination kit (ATPlite; PerkinElmer). AL18 did
not exhibit cytotoxicity in MDCK cells up to at least 250 M
(Table 1).We also tested the activity of AL18 on viral yield.MDCK
cells were infected with A/PR/8/34 at a multiplicity of infection
(MOI) of 0.01 and then treatedwithAL18 orRBVas a control, and
the viral titers in compound-treated and control cells were mea-
sured at 12, 24, and 48 h postinfection (p.i.). AL18 inhibited virus
yield with an EC50 of 2.5  0.9 M at 12 h, an EC50 of 4.5  1.5
M at 24 h, and an EC50 of 7.5 2.6 M at 48 h p.i. (Fig. 3B). As
expected, RBV also effectively reduced viral titers (Fig. 3B). In
time-of-addition experiments, performed as described in refer-
ence 9, inhibition was observed when AL18, or compound 1 for
comparison, was added preinfection or up to 2 h postinfection but
not at later time points (Fig. 3C). Thus, in contrast to M2 and
neuraminidase inhibitors, which block virus replication at earlier
and later stages, respectively (8, 21), both AL18 and compound 1
appear to act at early to middle stages, consistent with the obser-
vation of inhibition of the viral polymerase activity in minirepli-
con assays (Fig. 2).
To further evaluate the therapeutic potential and the antiviral
selectivity of AL18,we tested its effects on the replication of a panel
of other DNA and RNA viruses (Table 1): herpes simplex virus
type 1 (HSV-1; from the American Type Culture Collection
[ATCC], Manassas, VA), HCMV (from ATCC), human herpes-
virus 6 type A and type B (HHV-6A and HHV-6B; from L. Nae-
sens, Rega Institute for Medical Research, Leuven, Belgium), mu-
rine cytomegalovirus (MCMV; from D. Lembo, University of
Turin, Italy), human herpesvirus 8 (HHV-8; from C. Salata, Uni-
versity of Padua, Italy), adenovirus (AdV; from R. Cusinato,
Padua University Hospital, Italy), influenza B virus (B/Lee/40
strain), vesicular stomatitis virus (VSV), respiratory syncytial vi-
rus (RSV), measles virus (MV), and coxsackie virus B1 (COX B1)
(all RNAviruses except influenza B,whichwas fromW. S. Barclay,
Imperial College, London, United Kingdom, were from R. Cusi-
nato). The ability of AL18 to block virus growth was evaluated by
PRAs (for HSV-1, HCMV, MCMV, AdV, influenza B, VSV, RSV,
andMV), by quantification of viral DNAby quantitative real-time
PCR (for HHV6-A, HHV6-B, and HHV-8), or by estimation of
the cytopathic effect (for COXB1) as described previously (13, 14,
16). The antiviral drugs ganciclovir (GCV; from Sigma), foscarnet



















HSV-1 (F) Herpesviridae () dsDNA 50 250 5 1.6 0.7 250 156
HCMV (AD169) Herpesviridae () dsDNA 0.9 0.2 250 58 232 24 278 1.3 0.3 320 82 246
HHV-6A (GS) Herpesviridae () dsDNA 5.8 1.2 35.3 3.7 22.4 4.8 6 6.1 2.5 770 132 126
HHV-6B (Z29) Herpesviridae () dsDNA 6.1 2.6 38.0 6.7 25.6 5.7 6 3.7 1.9 980 144 265
MCMV (Smith) Herpesviridae () dsDNA 30 100 3 0.7 0.2 278 12 397
HHV-8 Herpesviridae () dsDNA 50 250 5 5.8 1.3 312 80 54
AdV Adenoviridae dsDNA 50 250 5 25.6 3.2 250 10
Influenza A (A/PR/8/34) Orthomyxoviridae () ssRNA 14.5 2.1 250 250 17 8.5 1.8 250 29
Influenza B (B/Lee/40) Orthomyxoviridae () ssRNA 8.3 1.9 250 250 30 18.3 2.6 250 14
MV Paramyxoviridae () ssRNA 50 250 5 85.4 5.8 250 3
RSV Paramyxoviridae () ssRNA 50 250 5 21.6 3.6 250 12
VSV Rhabdoviridae () ssRNA 50 250 5 10.3 2.9 250 24
COX B1 Picornaviridae () ssRNA 50 250 5 ND
a dsDNA, double-stranded DNA; ND, not determined; ssRNA, single-stranded RNA.
b Control compounds were GCV for HSV-1, HCMV, and HHV-8, FOS for HHV-6A and HHV-6B, CDV for MCMV and AdV, and RBV for all RNA viruses except COX B1.
c EC50, the concentration of compound that inhibits 50% of virus replication, was determined by PRAs for HCMV, HSV-1, MCMV, AdV, influenza A, influenza B, MV, RSV, and
VSV, by quantitative real-time PCR for HHV-6 and HHV-8, and by estimation of cytopathic effect for COX B1.
d CC50, the concentration of compound that inhibits 50% of cell growth, was determined in different cell lines by MTT assays and by ATP assays and was calculated by linear
regression using GraphPad Prism 4.0. Cell lines were Vero for HSV-1, MV, and COX B1, HFF for HCMV, HSB-2 for HHV-6A, MOLT-3 for HHV-6B, NIH 3T3 for MCMV, BC-3
for HHV-8, A549 for AdV, MDCK for influenza A and influenza B, L929 for VSV, and HEp-2 for RSV.
e SI, the selectivity index as determined by the ratio between the CC50 determined by MTT assays and the EC50. CC50 and EC50 were determined under the same cell culture
conditions.
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(FOS; from Sigma), cidofovir (CDV; from Pfizer), and RBV were
used as reference compounds.
As previously reported (13), AL18 showed potent antiviral ac-
tivity against HCMV with a selectivity index (SI) comparable to
that of GCV (Table 1). Conversely, it was inactive against other
herpesviruses, such as HSV-1, HHV-8, or MCMV, but showed
some inhibitory activity against HHV-6A andHHV-6B (Table 1).
However, the latter activity may have been due in part to cytotox-
icity in the cell lines used to grow the HHV-6 viruses, as the SI
values were poor (Table 1). No significant antiviral activity was
seen against another DNA virus (adenovirus) or RNA viruses
other than influenza A and influenza B (Table 1). Remarkably,
AL18 exhibited an EC50 against influenza B (8.3  1.9 M) that
was comparable to that against influenza A (Table 1). Thus, AL18
has dual specificity, acting as a potent inhibitor of one or more
members from two evolutionarily distinct virus families: HCMV
and influenza A and B.
The activity of AL18 against both HCMV DNA polymerase
(13) and influenza A RNA polymerase was surprising and would
not have been predicted on the basis of any obvious sequence
similarity of the polymerase interaction domains. Indeed, the lack
of specific antiviral activity of AL18 against herpesviruses other
than HCMV was not completely unexpected. Previous studies
have shown that the molecular details of the HCMV UL54-UL44
interaction are quite different from those of the interaction be-
tween the counterparts from other herpesviruses (1, 2, 4, 11, 12,
22). Nevertheless, knowing the predicted target sites of the drug in
both systems allowed us to use molecular modeling to investigate
whether a plausible explanation for the dual specificity was able to
be found. In fact, by analyzing docked poses of AL18 with the
UL44 protein of HCMV DNA polymerase and with the PA sub-
unit of influenza A RNA polymerase (Fig. 4) using the FLAP (Fin-
gerprints for Ligands And Proteins) software (3), possible molec-
ular explanations for the dual anti-HCMV and anti-influenza
activities of the compoundwere able to be proposed. According to
the FLAP docking poses with HCMV UL44 (Fig. 4A), AL18
strongly interacts with three residues in the central part of the
so-called “connector loop,” a region of UL44 shown to be crucial
for UL54 binding (1, 12). In particular, the two anilinic groups of
AL18 form hydrogen bonds with D134 and R137. Additionally,
the side chain of I135 is positioned as a hydrophobic anchor un-
derneath the hydrogen-bonding network of AL18, mimicking the
behavior already observed for UL54 binding by UL44 (1). Fur-
thermore, a second set of weaker hydrogen-bonding interactions
might occur between the carbonyl and hydroxyl groups of AL18 at
positions 10 and 4 and the T41 and T79 residues of UL44, respec-
tively. Inspecting the top 10 docking solutions, eight out of 10
poses of AL18 in UL44 are in agreement with the binding mode
reported in Fig. 4A. Compound 1 was reported to not inhibit
HCMV replication (16). Nine out of the 10 best FLAP poses of
compound 1 in UL44 (Fig. 4B) are located in a more external
binding region (inset in Fig. 4B), and thus, being highly exposed at
FIG 4 Molecular basis of the interaction of AL18 and compound 1 with the UL44 subunit of HCMVDNA polymerase and the PA subunit of influenza A RNA
polymerase. (A andB) FLAPbest pose for AL18 (A) and compound 1 (B) inHCMVUL44. The inset in panel B shows the 10 best poses for compound 1 inHCMV
UL44: nine out of 10 poses (in wireframe style) are clustered in a more external binding region. (C and D) FLAP best pose for AL18 (C) and compound 1 (D) in
influenza A PA. Flexibility of the K643 side chain in influenza A PA was considered. In all panels, the residues of the protein target that interacts with AL18 or
compound 1 are reported in sticks mode. The indicated AL18-binding residues of influenza A PA are conserved in influenza B.
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the UL44 surface, compound 1 may be easily displaced. The only
pose predicted at the same AL18 and UL54 binding regions is
driven by hydrophobic interactions only, while H-bond interac-
tions do not occur.
By analyzing FLAP docked poses with influenza A PA, AL18
(Fig. 4C) appears to be docked in the same binding region of
compound 1 (Fig. 4D) in the PA cavity (16). Looking at the best 10
poses in terms of FLAP similarity scores, all of them display the
same binding region. Seven poses out of 10 are oriented as re-
ported in Fig. 4C. The aromatic moiety of AL18 is involved in a
	-	 stacking with W706. Furthermore, AL18 forms a hydrogen-
bonding network with the N412, Q408, and K643 residues. All the
mentioned AL18-interacting residues of PA are highly conserved
among influenza A virus strains (6), suggesting that AL18 will
likely have broad-spectrum activity against influenza A viruses of
both human and animal origin. Intriguingly, these residues of
influenza A PA are also conserved in influenza B and match well
upon structural alignment (16). Thus, the FLAP docking pose is
also in agreement with the experimentally observed inhibition of
both influenza A and influenza B replication by AL18. The re-
maining three poses of AL18 in influenza A PA overlap the other
poses, but the structures are oppositely oriented, having the hy-
droxyl moiety pointed toward the N412 residue. Due to the spe-
cific structure of AL18, the hydrogen-bonding network, as well as
the hydrophobic interaction withW706, is largely retained also in
the second binding mode.
In contrast to AL18 and compound 1, AL5 docking into the
influenza A PA cavity seems to be driven mainly by hydrophobic
interactions involving theW706 residue (data not shown). All the
best 10 poses for AL5 are perfectly matching. The lack of an H-
bond network can be responsible for a weak interaction of AL5
with PA, which may explain the lack of anti-influenza activity of
AL5.Mutagenesis studies to confirm themolecularmodeling pre-
dictions are planned.
In conclusion, the AL18 compound exhibits anti-influenza A
and anti-influenza B activity with a potency comparable to that of
compound 1, a recently identified antiviral agent that acts by the
same mechanism (16). Unlike compound 1, however, AL18 also
possesses potent anti-HCMV activity. Thus, these data suggest
that AL18 merits further consideration as a starting point for the
development of new antiviral agents.
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